Loading your page…
5 companies in 3 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
1–25 of 90
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADRENALINA AGUETTANTSoluzione iniettabile in siringa pre-riempita | Epinephrine | Italy | Authorised | |
| ADRENALINA AGUETTANT 0,1 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA1,819 mg · Solución inyectable en jeringa precargada | Epinephrine | Spain | Marketed | 2016 |
| Adrenaline Aguettant 0,1 mg/ml, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Epinephrine | Netherlands | Authorised | 2015 |
| ATROPINA AGUETTANT 0,1 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA0,5 mg · Solución inyectable en jeringa precargada | Atropine | Spain | Marketed | 2016 |
| ATROPINA AGUETTANT 0,2 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA1 mg · Solución inyectable en jeringa precargada | Atropine | Spain | Marketed | 2016 |
| ATROPINA SOLFATO AGUETTANTSoluzione iniettabile | Atropine | Italy | Authorised | |
| ATROPINA SOLFATO LABORATOIRE AGUETTANTSoluzione iniettabile in siringa pre-riempita | Atropine | Italy | Authorised | |
| ATROPINE SULFATE INJECTION3 mg / 10 ml · Solution | Atropine | Canada | Authorised | |
| ATROPINE SULFATE INJECTION1 mg / 5 ml · Solution | Atropine | Canada | Marketed | 2015 |
| ATROPINE SULFATE INJECTION0.5 mg / 5 ml · Solution | Atropine | Canada | Marketed | 2015 |
| Atropinesulfaat Aguettant 0,1 mg/ml, oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Atropine | Netherlands | Authorised | 2015 |
| Atropinesulfaat Aguettant 0,2 mg/ ml, oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Atropine | Netherlands | Authorised | 2016 |
| BUPIVACAINA AGUETTANTSoluzione iniettabile | Bupivacaine | Italy | Authorised | |
| Bupivacaïne Glucose Aguettant 5 mg/ml oplossing voor injectieOplossing voor injectie | Bupivacaine | Netherlands | Authorised | 2025 |
| CARBETOCINA AGUETTANTSoluzione iniettabile | Carbetocin | Italy | Authorised | |
| Comboval 10 mg/ml + 3 mg/ml oplossing voor infusieOplossing voor infusie | Ibuprofen, Paracetamol | Netherlands | Authorised | 2022 |
| COMBOVAL 10 MG/ML + 3 MG/ML SOLUCIÓN PARA PERFUSIÓN10 mg/ml + 3,85 mg/ml · Solución para perfusión | Paracetamol, Ibuprofen | Spain | Authorised | 2023 |
| Droperidol Aguettant 2,5 mg/ml oplossing voor injectieOplossing voor injectie | Droperidol | Netherlands | Authorised | 2025 |
| DROPERIDOL AGUETTANT 2,5 MG/ML SOLUCION INYECTABLE EFG2,5 mg/ml · Solución inyectable | Droperidol | Spain | Marketed | 2025 |
| DROPERIDOLO AGUETTANTSoluzione iniettabile | Droperidol | Italy | Authorised | |
| Dzuveo | Sufentanil | EU (EMA) | Authorised | 2018 |
| DZUVEOCompressa sublinguale | Sufentanil | Italy | Authorised | |
| Dzuveo 30 microgram tabletten voor sublinguaal gebruikTablet voor sublinguaal gebruik | Sufentanil | Netherlands | Authorised | 2018 |
| DZUVEO 30 MICROGRAMOS COMPRIMIDO SUBLINGUAL0,045 mg · Comprimido sublingual | Sufentanil | Spain | Marketed | 2022 |
| EFEDRINA AGUETTANTSoluzione iniettabile | Ephedrine | Italy | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 29 | 29 | 0 | CompaniesAll medicines |
| Spain | 22 | 22 | 0 | CompaniesAll medicines |
| Italy | 20 | 20 | 0 | CompaniesAll medicines |
| Saudi Arabia | 9 | 9 | 0 | CompaniesAll medicines |
| Canada | 8 | 8 | 0 | CompaniesAll medicines |
| European Union (EMA) | 2 | 1 | 1 | CompaniesAll medicines |
Also in the registers of Croatia, France, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
